Y-mAbs Therapeutics reports Q2 EPS (7c), consensus (25c)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 08 2025
0mins
Should l Buy ?
Q2 Revenue Performance: The company reported a Q2 revenue of $19.5 million, exceeding the consensus estimate of $18.4 million.
Financial Outlook: This positive revenue result indicates stronger-than-expected financial performance for the quarter.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
